At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
Olanzapine +1 moredrug
Likely dose
Olanzapine 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Atypical Antipsychotic Medication in Anorexia Nervosa
In Brief
A Phase 2 clinical trial evaluating Olanzapine and Placebo for Eating Disorders. Completed, enrolled 23 participants across 1 site.
Detailed Summary
This study will evaluate the effectiveness of the antipsychotic medication olanzapine in treating outpatients with anorexia nervosa.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEating Disorders
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2005
First PostedJun 2008
Primary CompletionSep 2010
TodayJul 2026
First PostedJun 6, 2008
Enrollment StartOct 1, 2005
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 18.1 years ago
Interventions
Olanzapinedrug
Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of olanzapine once each evening for 8 weeks.
Placebodrug
Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of placebo once each evening for 8 weeks.